Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.
Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Mu TT, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Zhang YH, Wang H, Xia W, Sun LJ, Dai LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Hu M, Liu X, Lu RJ, Hu JH, Sun CC, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H. Su B, et al. Among authors: zheng yh, zheng qs. J Infect. 2022 Sep;85(3):334-363. doi: 10.1016/j.jinf.2022.05.034. Epub 2022 Jun 1. J Infect. 2022. PMID: 35659547 No abstract available.
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Xia W, Sun LJ, Dai LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Lu RJ, Hu JH, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H; TALENT Study Team. Su B, et al. Among authors: zheng yh, zheng qs. Chin Med J (Engl). 2020 Nov 25;133(24):2919-2927. doi: 10.1097/CM9.0000000000001273. Chin Med J (Engl). 2020. PMID: 33252379 Free PMC article. Clinical Trial.
Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial.
Zhan YQ, Chen RF, Zheng QS, Li XW, Liu YN, Mootsikapun P, Chayakulkeeree M, Arttawejkul P, Lan TTN, Liu GG, Lu HZ, Liu QQ, Zhong NS, Yang ZF, Zheng JP. Zhan YQ, et al. Among authors: zheng jp, zheng qs. J Thorac Dis. 2023 May 30;15(5):2859-2872. doi: 10.21037/jtd-23-281. Epub 2023 Apr 23. J Thorac Dis. 2023. PMID: 37324081 Free PMC article.
Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.
Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS. Hu K, et al. Phytomedicine. 2021 May;85:153242. doi: 10.1016/j.phymed.2020.153242. Epub 2020 May 16. Phytomedicine. 2021. PMID: 33867046 Free PMC article. Clinical Trial.
273 results